Show simple item record

dc.contributor.authorShaikh, Furqan
dc.contributor.authorStark, Daniel
dc.contributor.authorFonseca, Adriana
dc.contributor.authorDang, Ha
dc.contributor.authorXia, Caihong
dc.contributor.authorKrailo, Mark
dc.contributor.authorPashankar, Farzana
dc.contributor.authorRodriguez-Galindo, Carlos
dc.contributor.authorOlson, Thomas A
dc.contributor.authorNicholson, James C
dc.contributor.authorMurray, Matthew
dc.contributor.authorAmatruda, James F
dc.contributor.authorBillmire, Deborah
dc.contributor.authorStoneham, Sara
dc.contributor.authorFrazier, A Lindsay
dc.date.accessioned2020-09-22T23:30:55Z
dc.date.available2020-09-22T23:30:55Z
dc.date.issued2021-01-15
dc.identifier.issn0008-543X
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/310598
dc.description.abstractBACKGROUND: Adolescents with extracranial metastatic germ cell tumors (GCTs) are often treated with regimens developed for children, but their clinical characteristics more closely resemble those of young adult patients. This study was designed to determine event-free survival (EFS) for adolescents with GCTs and compared them with children and young adults. METHODS: An individual patient database of 11 GCT trials was assembled: 8 conducted by pediatric cooperative groups and 3 conducted by an adult group. Male patients aged 0 to 30 years with metastatic, nonseminomatous, malignant GCTs of the testis, retroperitoneum, or mediastinum who were treated with platinum-based chemotherapy were included. The age groups were categorized as children (0 to <11 years), adolescents (11 to <18 years), and young adults (18 to ≤30 years). The study compared EFS and adjusted for risk group by using Cox proportional hazards analysis. RESULTS: From a total of 2024 individual records, 593 patients met the inclusion criteria: 90 were children, 109 were adolescents, and 394 were young adults. The 5-year EFS rate was lower for adolescents (72%; 95% confidence interval [CI], 62%-79%) than children (90%; 95% CI, 81%-95%; P = .003) or young adults (88%; 95% CI, 84%-91%; P = .0002). The International Germ Cell Cancer Collaborative Group risk group was associated with EFS in the adolescent age group (P = .0020). After adjustments for risk group, the difference in EFS between adolescents and children remained significant (hazard ratio, 0.30; P = .001). CONCLUSIONS: EFS for adolescent patients with metastatic GCTs was similar to that for young adults but significantly worse than for that children. This finding highlights the importance of coordinating initiatives across clinical trial organizations to improve outcomes for adolescents and young adults. LAY SUMMARY: Adolescent males with metastatic germ cell tumors (GCTs) are frequently treated with regimens developed for children. In this study, a large data set of male patients with metastatic GCTs across different age groups has been built to understand the outcomes of adolescent patients in comparison with children and young adults. The results suggest that adolescent males with metastatic GCTs have worse results than children and are more similar to young adults with GCTs. Therefore, the treatment of adolescents with GCTs should resemble therapeutic approaches for young adults.
dc.format.mediumPrint-Electronic
dc.languageeng
dc.publisherWiley
dc.rightsAll rights reserved
dc.subjectHumans
dc.subjectNeoplasms, Germ Cell and Embryonal
dc.subjectRetroperitoneal Neoplasms
dc.subjectTesticular Neoplasms
dc.subjectMediastinal Neoplasms
dc.subjectLymphatic Metastasis
dc.subjectAntineoplastic Agents
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectRetrospective Studies
dc.subjectAdolescent
dc.subjectAdult
dc.subjectChild
dc.subjectChild, Preschool
dc.subjectInfant
dc.subjectInfant, Newborn
dc.subjectMale
dc.subjectYoung Adult
dc.subjectProgression-Free Survival
dc.titleOutcomes of adolescent males with extracranial metastatic germ cell tumors: A report from the Malignant Germ Cell Tumor International Consortium.
dc.typeArticle
prism.endingPage202
prism.issueIdentifier2
prism.publicationDate2021
prism.publicationNameCancer
prism.startingPage193
prism.volume127
dc.identifier.doi10.17863/CAM.57695
dcterms.dateAccepted2020-09-21
rioxxterms.versionofrecord10.1002/cncr.33273
rioxxterms.versionAM
rioxxterms.licenseref.urihttp://www.rioxx.net/licenses/all-rights-reserved
rioxxterms.licenseref.startdate2021-01
dc.contributor.orcidFonseca, Adriana [0000-0002-6382-6833]
dc.contributor.orcidMurray, Matthew [0000-0002-4480-1147]
dc.identifier.eissn1097-0142
rioxxterms.typeJournal Article/Review
pubs.funder-project-idSt Baldrick's Foundation (via Dana-Farber Cancer Institute) (2015-0743)
cam.issuedOnline2020-10-20
cam.orpheus.successMon Nov 02 07:31:11 GMT 2020 - Embargo updated
cam.orpheus.counter4
rioxxterms.freetoread.startdate2021-10-20


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record